Stoke and Biogen to present Zorevunersen clinical data at EEC
Stoke Therapeutics and Biogen announced presentations of clinical data from studies of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in September.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September…